This clinical trial evaluates the use of a self-guided web-based art therapy application (app), Art Therapy Can Do (ARTCan), for improving quality of life in young cancer survivors. Art therapy is a treatment that uses the making of art and the response to art to improve one's physical, mental, and emotional well-being. Studies have shown that art therapy has significant positive effects on the symptoms of mental illness and well-being yet this treatment is not accessible to many people. Offering art therapy using a digital app may increase the access of this service since most Americans own a smartphone. ARTCan, a self-guided web-based art therapy app, may be an acceptable way to provide art therapy and improve the quality of life of young cancer survivors.
Additional locations may be listed on ClinicalTrials.gov for NCT06789666.
Locations matching your search criteria
United States
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer CenterStatus: Active
Contact: Soma Sengupta
Phone: 919-966-8178
PRIMARY OBJECTIVE:
I. To investigate the feasibility of the usage of a digital app for art therapy in young cancer survivors.
SECONDARY OBJECTIVE:
I. To evaluate the acceptability of the digital art therapy application for young adult cancer survivors.
EXPLORATORY OBJECTIVES:
I. To evaluate the change from baseline in Patient-Reported Outcome Measurement Information System Depression Short Form (PROMIS-DSF) 8a scores after 6 weeks of ARTCan App art therapy application intervention in young cancer survivors.
II. To describe the patient’s quality of life before and during the ARTCan App art therapy application intervention in young cancer survivors.
OUTLINE:
Patients receive access to the ARTCan app, complete virtual guided art therapy activities once weekly for 6 weeks, and create and submit 1-5 photos of their art to the ARTCan app over 6 weeks.
After completion of study intervention, patients are followed up to 30 days.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationUNC Lineberger Comprehensive Cancer Center
Principal InvestigatorSoma Sengupta